Innoviva (INVA) Gross Margin (2011 - 2026)
Innoviva's (INVA) quarterly Gross Margin came in at 77.39% in Q1 2026, down 533.0% YoY from 17.87% in Q1 2025, and down 1.03% on a QoQ basis from 78.19% in Q3 2025.
Powered by 
Analysis
Innoviva (INVA) Gross Margin (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 9 years of Gross Margin data on file, last reported at 77.39% in Q1 2026.
- Quarterly Gross Margin fell 533.0% year-over-year to 77.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 93.59% (down 198.0% YoY) and the FY2025 annual result came in at 74.8%, down 778.0% from the prior year.
- Gross Margin slipped to 77.39% in Q1 2026, from 78.19% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 2409.3% in Q1 2024 to a low of 217.62% in Q2 2023.
- A 5-year average of 237.77% and a median of 82.91% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin soared 239593 bps — and 2025, when it slumped 232658 bps.
- Tracing INVA's Gross Margin over 5 years: stood at 98.61% in 2022, then gained by 1 bps to 99.29% in 2023, then declined by 18 bps to 81.71% in 2024, then slipped by 4 bps to 78.19% in 2025, then decreased by 1 bps to 77.39% in 2026.
- The last three Gross Margin figures came in at 77.39% (Q1 2026), 78.19% (Q3 2025), and 82.91% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 75.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.77% |
| Mar 31, 2026 | 77.39% |
| Sep 30, 2025 | 78.19% |
| Jun 30, 2025 | 82.91% |
| Mar 31, 2025 | 82.72% |
| Sep 30, 2024 | 81.71% |
| Jun 30, 2024 | 85.07% |
| Mar 31, 2024 | 77.53% |
| Sep 30, 2023 | 87.57% |
| Jun 30, 2023 | 88.91% |
| Mar 31, 2023 | 88.54% |
| Sep 30, 2022 | 98.61% |
| Jun 30, 2022 | 100.00% |
| Mar 31, 2022 | 100.00% |
| Sep 30, 2021 | 100.00% |
| Mar 31, 2014 | 75.90% |
| Mar 31, 2013 | 100.00% |
| Dec 31, 2011 | 100.00% |
| Sep 30, 2011 | 100.00% |
| Jun 30, 2011 | 81.58% |